Wide Ranks

BIIB

Biogen Inc.

159.83

Top Statistics
Market Cap 23 B Forward PE 9.59 Revenue Growth -2.50 %
Current Ratio 1.26 Trailing PE 14.45 Earnings Growth 0.00 %
Profit Margins 16.81 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 9.79 Enterprise / Revenue 2.94 Price To Sales Trailing12 Months 2.42
Profitability
Profit Margins 16.81 % Operating Margins 20.74 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 11.66 Total Debt 6 B
Total Debt To Equity 40.66 Current Ratio 1.26 Book Value Per Share 112.28
All Measures
Short Ratio 174.00 % Message Board Id finmb_29726 Shares Short Prior Month 3 M
Return On Equity 0.1047 City Cambridge Uuid 9f757b3b-bb17-33fd-9f97-b619c9193382
Previous Close 157.69 First Trade Date Epoch Utc 685 M Book Value 112.28
Beta -0.0610 Total Debt 6 B Volume 1 M
Price To Book 1.42 Last Split Date 979 M Fifty Two Week Low 153.62
Total Cash Per Share 11.66 Total Revenue 9 B Shares Short Previous Month Date 1 B
Target Median Price 251.00 Max Age 86400 Recommendation Mean 1.97
Sand P52 Week Change 0.3133 Operating Margins 20.74 % Target Mean Price 251.70
Net Income To Common 1 B Short Percent Of Float 0.0209 Implied Shares Outstanding 145 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 1 B Next Fiscal Year End 1 B
Revenue Per Share 66.12 Held Percent Insiders 0.0015 Ebitda Margins 30.03 %
Trailing PE 14.45 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 157.69 Target Low Price 180.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 179.46 Open 158.65 Free Cashflow 2 B
State MA Dividend Yield 0.00 % Return On Assets 0.0499
Time Zone Short Name EST Trailing Eps 11.06 Day Low 158.50
Address1 225 Binney Street Shares Outstanding 145 M Price Hint 2
Target High Price 342.00 Website https://www.biogen.com 52 Week Change -0.3172
Average Volume 1 M Forward Eps 16.66 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 68.00 % Last Split Factor 3:1
Regular Market Day High 160.72 Is_sp_500 True Profit Margins 16.81 %
Debt To Equity 40.66 Fifty Two Week High 268.30 Day High 160.72
Shares Short 2 M Regular Market Open 158.65 Industry Key drug-manufacturers-general
Earnings Growth 0.00 % Enterprise To Revenue 2.94 Revenue Growth -2.50 %
Shares Percent Shares Out 0.0185 Operating Cashflow 2 B Currency USD
Time Zone Full Name America/New_York Market Cap 23 B Is_nasdaq_100 True
Zip 02142 Quote Type EQUITY Industry Drug Manufacturers - General
Long Name Biogen Inc. Regular Market Day Low 158.50 Held Percent Institutions 0.9293
Current Price 159.83 Enterprise To Ebitda 9.79 Financial Currency USD
Current Ratio 1.26 Gross Margins 75.59 % Industry Disp Drug Manufacturers - General
Number Of Analyst Opinions 29 Country United States Float Shares 145 M
Two Hundred Day Average 206.63 Ir Website http://www.biogenidec.com/INVESTORS.aspx?ID=5494 Enterprise Value 28 B
Price To Sales Trailing12 Months 2.42 Forward PE 9.59 Regular Market Volume 1 M
Ebitda 2 B Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development.

It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co.

, Ltd.

; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co.

, Ltd.

; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain.

The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.